To the full analysis
Aurobindo Pharma stock: growth
AUROPHARMA.NSAurobindo Pharma reported $3.58B in revenue for fiscal 2026, up 6.1% on the prior year, up 6.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.7%
per year from 2007 to 2026, per share 15.1%
Earnings (Annual rate)
16.2%
per year from 2007 to 2026, per share 15.7%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 6.3% | 9.3% | 15.7% |
| Revenue per share | 6.5% | 9.4% | 15.1% |
| Earnings | −8.1% | 5.6% | 16.2% |
| Earnings per share | −7.9% | 5.7% | 15.7% |
| Free cash flow | 14.2% | no data | no data |
| Free cash flow per share | 14.4% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $225.64M | $21.36M | −$33.29M |
| 2008 | $258.91M | $25.35M | −$9.31M |
| 2009 | $327.08M | $10.66M | −$36.88M |
| 2010 | $380.03M | $59.62M | $940.65K |
| 2011 | $465.7M | $59.89M | −$40.54M |
| 2012 | $482.36M | −$13.13M | −$26.05M |
| 2013 | $624.07M | $31.23M | $171.12K |
| 2014 | $1.29B | $167.49M | $27.19M |
| 2015 | $1.29B | $167.49M | $49.8M |
| 2016 | $1.47B | $215.24M | −$15.51M |
| 2017 | $1.59B | $244.64M | $168.41M |
| 2018 | $1.75B | $257.56M | $45.16M |
| 2019 | $2.08B | $251.34M | $9.76M |
| 2020 | $2.46B | $302.41M | $313.57M |
| 2021 | $2.63B | $567.03M | $154.68M |
| 2022 | $2.49B | $281.47M | $245.72M |
| 2023 | $2.64B | $204.87M | −$35.46M |
| 2024 | $3.08B | $337.25M | −$119.78M |
| 2025 | $3.37B | $370.51M | $207.98M |
| 2026 | $3.58B | $372.51M | $300.51M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Apr 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.